Myelodysplastic Syndromes-Many New Drugs, Little Therapeutic Progress

被引：11
作者：
Tefferi, Ayalew [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA
来源：
MAYO CLINIC PROCEEDINGS | 2010年 / 85卷 / 11期
关键词：
ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; IRON CHELATION-THERAPY; HIGH-RISK; PHASE-III; PROGNOSTIC-FACTORS; SCORING SYSTEM; SERUM FERRITIN; UNITED-STATES; 5Q DELETION;
D O I：
10.4065/mcp.2010.0502
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1042 / 1045
页数：4
相关论文
共 50 条
[31]   From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review [J].
Comont, Thibault ;
Treiner, Emmanuel ;
Vergez, Francois .
DIAGNOSTICS, 2021, 11 (11)
[32]   Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes [J].
Ivy, Kathryn S. ;
Ferrell, P. Brent, Jr. .
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (04) :244-255
[33]   Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms [J].
Stempel, Jessica M. ;
Xie, Zhuoer ;
Bewersdorf, Jan Philipp ;
Stahl, Maximilian ;
Zeidan, Amer M. .
CANCER JOURNAL, 2023, 29 (03) :203-211
[34]   Interpreting new molecular genetics in myelodysplastic syndromes [J].
Abdel-Wahab, Omar ;
Figueroa, Maria E. .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2012, :56-64
[35]   Prognosis in myelodysplastic syndromes: Are the new classifications useful? [J].
Galili N. ;
Raza A. .
Current Hematologic Malignancy Reports, 2008, 3 (1) :19-22
[36]   Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights [J].
Platzbecker, Uwe .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2013, :522-528
[37]   Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise? [J].
Nazha, Aziz ;
Sekeres, Mikkael A. ;
Gore, Steven D. ;
Zeidan, Amer M. .
ONCOLOGIST, 2015, 20 (09) :1069-1076
[38]   The Genetic Basis and Expanding Role of Molecular Analysis in the Diagnosis, Prognosis, and Therapeutic Design for Myelodysplastic Syndromes [J].
Nybakken, Grant E. ;
Bagg, Adam .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2014, 16 (02) :145-158
[39]   Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions [J].
Shyamala C. Navada ;
Lewis R. Silverman .
Current Hematologic Malignancy Reports, 2011, 6 :5-12
[40]   Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications [J].
Fozza, Claudio ;
Murtas, Andrea ;
Caocci, Giovanni ;
La Nasa, Giorgio .
LEUKEMIA RESEARCH, 2022, 117
12345